SHANGHAI, CHINA, September 25, 2025 - JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that its enhanced Fast CAR-T product JWCAR239, targeting CD19/CD20, has completed the first patient infusion in its clinical study for relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).
Targeted CD19 CAR-T cell therapy represents a breakthrough treatment for patients with refractory/relapsed (r/r) B-cell non-Hodgkin lymphoma (B-NHL), demonstrating remarkable short-term efficacy. However, many patients remain unresponsive to initial treatment or experience relapse, with long-term progression-free survival (PFS) rates approximately 40%¹. Common mechanisms of refractory/relapse include antigen escape (e.g., loss of CD19 antigen expression), immunosuppressive microenvironments (e.g., inhibitory TGF-β signaling), and dysregulation of CAR-T cell-mediated cytotoxic pathways (e.g., apoptosis)².
Simultaneously targeting CD19/CD20 and enhancing CAR-T cells' resistance to immunosuppressive microenvironments and apoptotic signals represent key strategies for overcoming CAR-T resistance. In recent years, dual-targeted CAR-T cells targeting CD19/CD20 and fourth-generation CAR-T cells incorporating various enhancement elements have yielded preliminary safety and efficacy data in lymphoma patients.
Additionally, Fast CAR-T possesses unique characteristics compared to traditional CAR-T in terms of production processes and cellular properties, offering multiple advantages. It is gradually demonstrating promising prospects in the treatment of cancer and autoimmune diseases3.
JWCAR239 is a fast CAR-T cell product derived from patient-specific T cells genetically engineered to target CD19 and CD20. It prevents antigen escape while incorporating two exogenously transduced enhancement elements—dnFas-CD2 and dnTGFβRII—that enhance CAR-T cells' resistance to apoptosis (via CD58 downregulation) and their ability to counteract immunosuppressive signals in the tumor microenvironment. Its rapid manufacturing process not only significantly shortens production cycles but also yields CAR-T cells with a younger phenotype, preserving a high proportion of youthful Tscm cells. This results in enhanced in vivo expansion and tumor cell killing capacity. Preclinical studies have preliminarily validated its efficacy and safety. This study aims to conduct a preliminary assessment of JWCAR239's safety and/or efficacy in patients with r/r B-NHL.
- Nat Rev Clin Oncol. 2023 Apr 13:1–13. doi: 10.1038/s41571-023-00754-1.2.Transplantation and Cellular Therapy (2023), doi: https://doi.org/10.1016/j.jtct.2023.04.007
- Transplantation and Cellular Therapy (2023), doi: https://doi.org/10.1016/j.jtct.2023.04.007
- Lancet Haematol. 2025;12(1):e57-e67. doi:10.1016/S2352-3026(24)00273-4
About JW Therapeutics
JW Therapeutics (HKEx:2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products. Since its founding in 2016, JW Therapeutics has built an integrated platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors and autoimmune diseases. JW Therapeutics is committed to bringing breakthrough and quality cell immunotherapy products and the hope of a cure to patients in China and beyond, and to leading the healthy and standardized development of China’s cell immunotherapy industry. For more information, please visit www.jwtherapeutics.com.
About Relmacabtagene Autoleucel Injection
Relmacabtagene autoleucel injection (abbreviated as relma-cel, trade name for oncology indications: Carteyva®) is an autologous anti-CD19 CAR-T cell immunotherapy product independently developed by JW Therapeutics based on a CAR-T cell process platform of Juno Therapeutics (a Bristol Myers Squibb company). Being the first product of JW Therapeutics, Carteyva® has been approved by NMPA for three indications, including the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more lines of systemic therapy, the treatment of adult patients with follicular lymphoma that is refractory or that relapses within 24 months of second-line or above systemic treatment (r/r FL), and the treatment of adult patients with relapsed or refractory mantle cell lymphoma (r/r MCL) after two or more lines of systemic therapy including bruton tyrosine kinase inhibitors (BTKi), making it the first CAR-T product approved as a Category 1 biologics product in China. Currently, it is the CAR-T product in China that has been simultaneously included in the National Significant New Drug Development Program, priority review and breakthrough therapy designations.
Forward-Looking Statements
The forward-looking statements are based on the management's expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described. Significant risks and uncertainties, include those discussed below and more fully described in Hong Kong Exchanges and Clearing Limited (HKEx) reports filed by the Company. Unless otherwise noted, the Company is providing this information as of the date it publicized, and expressly disclaims any duty to update information contained in the issues and relevant information, or provide any explanation. For detailed information, please visit the company website: www.jwtherapeutics.com/en/forward-looking-statements/.